Aldeyra Therapeutics
ALDX

$6.13

3.01%

Market Cap: $364M

About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Employees: 10

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

395% more call options, than puts

Call options by funds: $1.08M | Put options by funds: $219K

20% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 15

3% more funds holding

Funds holding: 100 [Q1] → 103 (+3) [Q2]

6% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% less capital invested

Capital invested by funds: $117M [Q1] → $117M (-$26.3K) [Q2]

1.23% less ownership

Funds ownership: 60.71% [Q1] → 59.47% (-1.23%) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

63%

upside

Avg. target

$10

63%

upside

High target

$10

63%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Matthew Caufield 29% 1-year accuracy 12 / 41 met price target	63%upside $10	Buy Reiterated	9 Aug 2024
HC Wainwright & Co. Matthew Caufield 29% 1-year accuracy 12 / 41 met price target	63%upside $10	Buy Reiterated	2 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ALDX published over the past 30 days

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. Dr. Brady's conversation with Matthew Caufield, Director, Equity Research at H.C.

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership

Aldeyra Therapeutics' Reproxalap eye drop for Dry Eye Disease has new positive data for the second NDA attempt. Aldeyra has an option agreement with AbbVie, potentially leading to significant milestone payments and a 60%/40% partnership if FDA approval is granted. Reproxalap offers immediate and long-term relief, a significant advantage over existing therapies like Xiidra and Restasis, enhancing its market potential.

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership

Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%

Aldeyra Therapeutics Inc.'s ALDX Phase 3 dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution achieves the primary endpoint.

Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reprox.

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap. The dial-in numbers are (888) 596-4144 for domestic callers and (646) 968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the “Inv.

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today. Pipeline Updates Following positive biomarker results in adults, including near-normalization o.

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry eye disease. The trial is designed to enable potential resubmission of a dry eye dise.

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Aldeyra Therapeutics to Host Investor Roundtable Q&A

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET. The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session.

Aldeyra Therapeutics to Host Investor Roundtable Q&A

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission

Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye disease and allergic conjunctivitis. Aldeyra plans to resubmit Reproxalap's new drug application by Q4 2024, with potential FDA approval by Q2 2025, which could trigger potential milestone payments and revenue opportunities.

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Dr. Brady's conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jeff.

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference

See News Rankings